<DOC>
	<DOCNO>NCT00882674</DOCNO>
	<brief_summary>This 2 part study explore pharmacodynamic effect R1507 breast cancer tumor cell female patient operable breast cancer . In first part study , patient receive single dose R1507 , 16mg/kg iv , day 1 ; pre-and post-treatment ( breast surgery day 8 ) breast tissue sample obtain measurement IGF-1R expression . If sufficient biological activity demonstrate , 3 additional cohort patient enter Part 2 study , receive single dose 9mg , 3mg/kg 1mg/kg iv R1507 , respectively . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Evaluate Biological Activity R1507 Women With Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>female patient , &gt; =18 year age ; invasive , operable , breast cancer ; ECOG Performance Status 0 1. evidence metastatic disease ; inflammatory breast cancer ; prior hormonal systemic therapy breast cancer ; prior treatment agent targetting IGF1R pathway ; patient receive concurrent radiotherapy , receive radiotherapy within 28 day prior receipt study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>